Menu
← Oncology Approval Tracker
FDA DECISION ·
Opdivo Qvantig
nivolumab + hyaluronidase-nvhy · Bristol Myers Squibb
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
As subcutaneous monotherapy for adults with unresectable or metastatic MSI-high or mismatch repair-deficient colorectal cancer following intravenous nivolumab plus ipilimumab.
LAMPGEN ANALYSIS
Why it matters
The label provides a subcutaneous continuation option after the intravenous dual checkpoint regimen.
What research teams should watch
Set a clear handoff from IV combination therapy to subcutaneous monotherapy and retain the molecular testing record.
PRIMARY RECORDS